Richard Mason, Apollo Therapeutics CEO
September 6, 2023 11:01 AM EDT
Financing

UK biotech brings in $226M Se­ries C

Paul Schloesser

Associate Editor

Apol­lo Ther­a­peu­tics is reel­ing in a $226.5 mil­lion Se­ries C round, the biotech said Wednes­day.

The fi­nanc­ing is two-pronged: It aims …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Trump blog: Judge ex­tends na­tion­wide block on NIH pay­ment cuts

RFK Jr. read­ies re­view of child­hood vac­cine sched­ule af­ter pledg­ing not to

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times